Artificial intelligence is driving innovation across drug discovery and genomic sciences. New AI models generate novel antibiotic structures from minimal inputs, expediting antimicrobial development. Natera launches an AI foundational model platform integrating tumor exomes, clinical records, and imaging to enhance therapeutic development and clinical decision support. Twist Bioscience introduces a comprehensive oncology DNA profiling panel to identify genomic alterations guiding targeted treatments. These tools signify a paradigm shift toward AI-enabled precision medicine.